Landmark Alliance ATOMIC Trial Establishes New Standard of Care for Patients with Stage III dMMR Colon Cancer
Published results show adjuvant atezolizumab plus mFOLFOX6 significantly reduces recurrence risk and delivers the first proven immunotherapy benefit in early stage dMMR disease. A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly…